Relationship of Glycemic Control, Exogenous Insulin, and C-Peptide Levels to Ischemic Heart Disease Mortality Over a 16-Year Period in People With Older-Onset Diabetes
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—The purpose of this study was to examine the relationship of glycemic control and exogenous and endogenous insulin levels with all-cause and cause-specific mortality (ischemic heart disease and stroke) in an older-onset diabetic population. RESEARCH DESIGN AND METHODS—The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) is an ongoing, prospective, population-based cohort study of individuals with diabetes first examined in 1980–1982. A stratified sample of all individuals with diabetes diagnosed at 30 years of age or older was labeled “older-onset” (n = 1,370). Those participating in the 1984–1986 examination phase (n = 1,007) were included in the analysis. Endogenous insulin was determined by measurements of plasma C-peptide (in nanomoles per liter), and exogenous insulin was calculated in units per kilogram per day. Glycemic control was determined by levels of glycosylated hemoglobin (HbA1). RESULTS—After 16 years of follow-up, 824 individuals died (all-cause mortality); 358 deaths involved ischemic heart disease and 137 involved stroke. C-peptide and HbA1 were significantly associated with all-cause and ischemic heart disease mortality in our study. The hazard ratio (95% CI) values for all-cause mortality were 1.12 (1.07–1.17) per 1% increase in HbA1, 1.20 (0.85–1.69) per 1 unit · kg−1 · day−1 increase in exogenous insulin, and 1.15 (1.04–1.29) per 1 nmol/l increase in C-peptide and for ischemic heart disease mortality were 1.14 (1.06–1.22), 1.50 (0.92–2.46), and 1.19 (1.02–1.39) for HbA1, exogenous insulin, and C-peptide, respectively, after adjusting for relevant confounders. C-peptide was associated with stroke mortality only among men (1.65 [1.07–2.53]). CONCLUSIONS—Our results show that individuals with higher endogenous insulin levels are at higher risk of all-cause, ischemic heart disease, and stroke mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease.
Després, J. P., Moorjani, S., Lupien, P. J., Tremblay, A., Nadeau, A., & Bouchard, C. (1990) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.10.4.497 · Cited by 1,248
Intensive Diabetes Therapy and Carotid Intima–Media Thickness in Type 1 Diabetes Mellitus
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa022314 · Cited by 815 · cited 1×
“The Epidemiology of Diabetes Interventions and Complications (EDIC) study, a long-term follow-up of the DCCT, reported a slower rate of progression of arterial wall thickness (25) and a 42% reduced risk of cardiovascular events (26) in the intensive therapy group compared with the group under conventional treatment am…”
Result
Cited by
A practical review of C-peptide testing in diabetes
Leighton, E., Sainsbury, C. A., & Jones, G. C. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0265-4 · Cited by 773
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) · Diabetes Care · doi:10.2337/dc15-1990 · Cited by 712
Bains, S. S., & Egede, L. E. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0160 · Cited by 288
Schwingshackl, L., Strasser, B., & Hoffmann, G. (2011) · Annals of Nutrition and Metabolism · doi:10.1159/000331214 · Cited by 147
Metadata
- Authors
- Hirai, F. E., Moss, S. E., Klein, B. E. K., & Klein, R.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2008-03-01
- Volume
- 31
- Issue
- 3
- Pages
- 493-497
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2111806993
- Cited by
- 54
- References
- 2
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.